Growth Metrics

BeOne Medicines (BEIGF) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $1.1 billion.

  • BeOne Medicines' Total Non-Current Liabilities rose 20716.46% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 20716.46%. This contributed to the annual value of $373.8 million for FY2024, which is 1835.73% down from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Total Non-Current Liabilities is $1.1 billion, which was up 20716.46% from $318.1 million recorded in Q2 2025.
  • BeOne Medicines' Total Non-Current Liabilities' 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of $318.1 million in Q2 2025.
  • For the 5-year period, BeOne Medicines' Total Non-Current Liabilities averaged around $569.8 million, with its median value being $527.4 million (2022).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 3435.37% in 2022, then soared by 20716.46% in 2025.
  • BeOne Medicines' Total Non-Current Liabilities (Quarter) stood at $803.4 million in 2021, then tumbled by 34.35% to $527.4 million in 2022, then dropped by 13.19% to $457.8 million in 2023, then decreased by 18.36% to $373.8 million in 2024, then surged by 203.6% to $1.1 billion in 2025.
  • Its Total Non-Current Liabilities stands at $1.1 billion for Q3 2025, versus $318.1 million for Q2 2025 and $358.3 million for Q1 2025.